Addrenex acquires promising narcolepsy therapy from SK Holdings
This article was originally published in Scrip
Addrenex Pharmaceuticals has acquired global rights outside east Asian markets to SK Holdings' ADX-N05, an early development-stage molecule with potential in narcolepsy and other CNS indications.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.